Osoyoos Cannabis Inc. (CSE:OSO) (“the Company” or “Osoyoos Cannabis”) commences trading on the Canadian Stock Exchange (“CSE”) on February 21, 2019, under the symbol “OSO”.

There have been a number of significant developments within the Company leading up to our public debut that we wish to highlight to our valued investors.

Osoyoos Cannabis is advancing on a pathway to become a world-leading cannabinoid extraction company. Consequently, the Company has amended its original application for a Cultivation License under the ACMPR, to a Standard Processor License under the Cannabis Act. This application has been submitted through the Indigenous Navigator Program, which is expected to expedite the licensing process. Our application is currently in the review stage.

In furthering this strategy, Osoyoos Cannabis has secured a lease, with the option to purchase, a 10,410 ft2 facility on the Osoyoos Indian Band’s lands in the Senkulmen Business Park in Oliver, BC. The building and its location are perfectly suited for the purposes of cannabinoid extraction. The facility is a former storage warehouse that is in excellent condition and has the ideal dimensions to allow for a phased retrofit. Phase One of this retrofit is approximately 3,500 ft2. The initial architectural designs have been completed and the Company is advancing the build out.

To implement the operating model, Osoyoos Cannabis has purchased and taken possession of four Vitalis Supercritical CO2Extraction Systems, which will operate within the footprint of the Phase One retrofit. These Systems will allow for the processing of up to 50,000 kilograms of dried flower annually, which is expected to produce approximately 4,900 kilograms of winterized output per year.

The ongoing execution of our plan will allow Osoyoos Cannabis to pursue four core business lines:

1) Contract processing for third-party licensed producers, by performing tolling services for the extraction of pharmaceutical-grade, purified oil from cannabis or hemp;

2) Extraction and production of oils to be sold through wholesale contracts to third-party licensed producers;

3) Leverage our extraction expertise for the development of cannabis concentrates, product formulations and processing and packaging for ready to sell white-labelled products for third-party licensed producers; and

4) Manufacturing and distribution of our own proprietary Osoyoos Cannabis branded products for retail, allowing us to create greater margins upon sale and to build a lifestyle brand along the way.

Subsequent to the Phase One facility retrofit, which is expected to be completed in summer 2019, Osoyoos Cannabis will commence its Phase Two retrofit. This Phase will entail retrofitting the balance of the facility, adding more packaging equipment and doubling extraction capacity. Doing so will allow for the processing of up to 100,000 kilograms of flower annually which is expected to produce approximately 9,800 kilograms of output per year.

In addition to Osoyoos Cannabis’ application for a Standard Processing license, the Company is also in the process of negotiating a letter of intent relating to 100 acres of neighboring land with the intention of cultivating cannabis outdoors. The Okanagan Valley is the hottest and driest place in Canada, which is the ideal location to establish an outdoor grow. This low-cost cultivation method, combined with high-margin processing and product development expertise, will allow Osoyoos Cannabis to operate with some of the best economics in the industry.

Osoyoos Cannabis is excited to pursue these two fundamental strategies that capitalize on current industry themes: namely the production of cannabis concentrates and access to low cost input materials.

For a full description of the Company, readers are encouraged to review its Listing Statement dated February 20, 2019 which may be viewed at: www.SEDAR.com.



Interim CEO and Executive Chairman

For further information contact:

Gerry Goldberg | ggoldberg@osoyooscannabis.com | (416) 460-3000


Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the Company to become licensed in Canada to produce and sell cannabis extracts. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain the necessary corporate, regulatory and other third-party approvals; licensing and other risks associated with Cannabis Act (Canada) operations. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

Source: www.newsfilecorp.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less